What share of the HIV market does Biktarvy have?
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is commonly cited as a leading brand in the HIV treatment market, but market-share figures depend heavily on the dataset used (for example, prescriptions vs. patients treated vs. revenue) and the geography/time period. The provided information does not include any specific market-share numbers, so a precise percentage cannot be stated here.
How is Biktarvy market share measured (and why numbers differ)?
“Market share” can mean different things in HIV, and that’s why published estimates don’t always match:
- Share of prescriptions (often tracked by pharmacy claims)
- Share of patients on therapy (sometimes tracked by payer or health system datasets)
- Share by revenue (brand sales, sometimes adjusted for rebates/discounts)
- Share within a specific segment (commercial vs. Medicare/Medicaid, or first-line vs. all lines of therapy)
Without the underlying metric and geography, any single percentage would be incomplete.
What data sources typically report Biktarvy’s share?
Common sources used by industry watchers include:
- Prescription/claims datasets (often used for quarterly brand share trends)
- Company-reported or investor-deck commentary (usually framed as “leading” rather than a single point estimate)
- Payer or specialty pharmacy reporting
- Patent/lifecycle and competitive-intelligence summaries
The provided information doesn’t name any of these for Biktarvy with a specific share figure.
How does Biktarvy compare to other top HIV brands?
Biktarvy’s market position is usually discussed relative to other high-volume integrase inhibitor-based single-tablet regimens (for example, Gilead’s other INSTI options and competing fixed-dose combinations). Exact head-to-head share comparisons again require the same clarifications: geography, time, and whether the comparison is by prescriptions, patients, or sales.
Can you share the exact market-share statistic you want?
If you tell me:
1) the geography (US, EU5, global, etc.),
2) the timeframe (e.g., latest quarter, 2023 full year),
3) the metric (prescriptions, patients, or revenue),
I can help interpret what that market-share number means and how to compare it with competitors—but I’ll need a source or the specific figure you’re looking at since the current prompt provides none.
Sources
No sources were provided in the prompt.